Nanologica: Set up for Growth
Redeye views the year-end report as another positive step in the commercialization process. The past year has been heavily affected by the pandemic; however, there has been considerable progress on many fronts. We believe that the company has reached a growth inflection point. The estimates for the current year are unchanged apart from some issues of inventory change and activated costs.
We roll our model forward another year with a positive effect on the fair value in our DCF model. We raise our motivated value in our base case in our model to SEK 20(17) per share with a range from SEK 8(7) and 28(25) per share in the bear and bull case.